275 related articles for article (PubMed ID: 9795397)
21. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.
Monge S; Hahné SJ; de Melker HE; Sanders EA; van der Ende A; Knol MJ
Lancet Infect Dis; 2018 Jul; 18(7):749-757. PubMed ID: 29752131
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
23. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey.
Hoppenbrouwers K; Kanra G; Roelants M; Ceyhan M; Vandermeulen C; Yurdakök K; Silier T; Dupuy M; Pehlivan T; Ozmert E; Desmyter J
Vaccine; 1999 Feb; 17(7-8):875-86. PubMed ID: 10067694
[TBL] [Abstract][Full Text] [Related]
24. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
[TBL] [Abstract][Full Text] [Related]
26. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age.
Lin TY; Wang YH; Chang LY; Chiu CH; Huang YC; Tang H; Bock HL
Chang Gung Med J; 2003 May; 26(5):315-22. PubMed ID: 12934847
[TBL] [Abstract][Full Text] [Related]
29. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
30. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.
Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Kolasa M
MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):889-96. PubMed ID: 26313470
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P
Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
33. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.
Happe LE; Lunacsek OE; Kruzikas DT; Marshall GS
Pediatr Infect Dis J; 2009 Feb; 28(2):98-101. PubMed ID: 19148039
[TBL] [Abstract][Full Text] [Related]
34. Public health impact of Infanrix hexa (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 1: Evolution of hepatitis B vaccine coverage rates in infants aged less than 27 months, in the general population - the PopCorn study.
Gaudelus J; Vié le Sage F; Dufour V; Lert F; Texier N; Pouriel M; Tehard B; Bréart G
Rev Epidemiol Sante Publique; 2016 Feb; 64(1):23-32. PubMed ID: 26748972
[TBL] [Abstract][Full Text] [Related]
35. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
Bar-On ES; Goldberg E; Fraser A; Vidal L; Hellmann S; Leibovici L
Cochrane Database Syst Rev; 2009 Jul; (3):CD005530. PubMed ID: 19588375
[TBL] [Abstract][Full Text] [Related]
36. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
[TBL] [Abstract][Full Text] [Related]
37. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.
Boef AGC; van der Klis FRM; Berbers GAM; Buisman AM; Sanders EAM; Kemmeren JM; van der Ende A; de Melker HE; Rots NY; Knol MJ
Vaccine; 2018 Jan; 36(3):400-407. PubMed ID: 29223483
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the tolerability of newly introduced childhood vaccines in the Netherlands.
Kemmeren JM; van der Maas NA; de Melker HE
Eur J Pediatr; 2017 Jun; 176(6):757-768. PubMed ID: 28429115
[TBL] [Abstract][Full Text] [Related]
40. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
